title: Long-term intraocular pressure changes in patients with neovascular age-related macular degeneration treated with ranibizumab.
abstract: OBJECTIVE
  To investigate the long-term effects of multiple intravitreal injections (IVTs) of ranibizumab (Lucentis) on intraocular pressure (IOP) in patients with neovascular age-related macular degeneration.
  
  
  METHODS
  In 320 eyes, IOP measurements were performed at baseline prior to injection and compared with IOP measurements of the last visit. Correlations between mean IOP change and total number of IVTs, visual acuity or patient age were tested.
  
  
  RESULTS
  The mean IOP increase was 0.8 ± 3.1 mm Hg (p < 0.0001). Seven eyes showed final IOP values between 22 and 25 mm Hg. The mean follow-up was 22.7 ± 14.1 months. No further correlations between IOP change and number of IVTs, visual acuity or patient age have been found.
  
  
  CONCLUSIONS
  This study demonstrated a statistically significant IOP increase in patients treated with repeated injections of ranibizumab. However, IOP increase required no glaucoma treatment during the study. Therefore, repeated injections with ranibizumab can be considered safe with regard to long-term IOP changes in patients without ocular hypertension or glaucoma.
authors.affiliation: Department of Ophthalmology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland. marcel.menke@insel.ch
authors.forename: Marcel N
authors.initials: MN
authors.lastname: Menke
authors.forename: Adzura
authors.initials: A
authors.lastname: Salam
authors.forename: Carsten
authors.initials: C
authors.lastname: Framme
authors.forename: Sebastian
authors.initials: S
authors.lastname: Wolf
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D000069579:Ranibizumab; D019233:Retreatment; D012189:Retrospective Studies; D014065:Tonometry, Ocular; D014792:Visual Acuity / Q000187:drug effects; D057135:Wet Macular Degeneration / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab